Ultrasensitive Detection of Target micro-RNAs and Nucleic Acids in Small Volume Blood Samples of Advanced Stage Prostate and Kidney Cancer Patients

Overview

About this study

The purpose of this study is to evaluate the feasibility of successfully obtaining serial finger-prick blood samples from castrate resistant prostate cancer and metastatic renal cell cancer patients using a specific (HemaSpot-SE ™) collection kit.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Diagnosis of castrate resistant prostate cancer based on standard of clinical care definitions either beginning or receiving standard of care treatments for castrate resistant disease including docetaxel chemotherapy; abiraterone acetate; prednisone;  enzalutamide; immunotherapy; cabazitaxel or mitoxantrone  chemotherapy or radium-223.
  • Diagnosis of metastatic kidney cancer based on standard of clinical care definitions either beginning or receiving standard of care treatments for metastatic kidney cancer including VEGF inhibition; biotherapy; immunotherapy or m-TOR inhibitors.
  • Willing to learn to perform a finger prick daily for six days and to be able to use a mail-in Federal Express/UPS kit for shipment.

Exclusion Criteria:

  • Unwilling to perform a finger prick for blood draw or unable to follow directions
  • Bleeding tendencies (known hemophilia; bleeding diathesis, etc)
  • On anti-coagulation using Coumadin; heparin, direct thrombin inhibitors (or similar) medications as part of standard clinical care (aspirin, Plavix like medications or other non-steroidal medication use is not an exclusion factor).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Manish Kohli, M.D.

Closed for enrollment

Rochester, Minn.

Mayo Clinic principal investigator

Manish Kohli, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20391186

Mayo Clinic Footer